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Abstract 
Involvement of the peripheral nervous system in mitochondrial disorders has been previously reported. However, the prevalence of peripheral 
neuropathy in mitochondrial disorders is still unclear. Based on the large database of the “Nation-wide Italian Collaborative Network of 
Mitochondrial Diseases”, we reviewed the clinical data of 1200 patients, with special regard to peripheral neuropathy (mean age at onset 
24.3 ± 20.1 years; age at last evaluation 39.8 ± 22.3 years; females 52.7%; childhood onset [before age 16 years] 43.1%). Peripheral neuropathy 
was present in 143/1156 patients (12.4%), being one of the ten most common signs and symptoms. POLG mutations cause a potentially painful, 
axonal/mixed, mainly sensory polyneuropathy; TYMP mutations lead to a demyelinating sensory-motor polyneuropathy; SURF1 mutations are 
associated with a demyelinating/mixed sensory-motor polyneuropathy. The only mtDNA mutation consistently associated with peripheral 
neuropathy (although less severely than in the above-considered nuclear genes) was the m.8993T > G (or the rarer T > C) changes, which lead to 
an axonal, mainly sensory polyneuropathy. In conclusion, peripheral neuropathy is one of the most common features of a mitochondrial disorder, 
and may negatively impact on the quality of life of these patients. Furthermore, the presence or absence of peripheral neuropathy, as well as its 
speciﬁc forms and the association with neuropathic pain (indicative of a POLG-associated disease) can guide the molecular analysis. 
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The central task of mitochondria is to generate energy in the 
form of adenosine triphosphate, through the electron transport 
chain and oxidative phosphorylation (OXPHOS) [1]. This 
pathway is under control of both nuclear and mitochondrial 
(mtDNA) genomes. Mitochondrial diseases are a group of 
disorders caused by OXPHOS impairment. They are one 
of the commonest inherited neuromuscular diseases, with 
an estimated prevalence of 1–2 in 10,000. The genetic 
classiﬁcation distinguishes the disorders due to defects in 
mtDNA from those due to defects in nuclear DNA. 
Both mtDNA and nuclear mutations affecting OXPHOS 
usually result in multisystem clinical phenotypes, including 
peripheral neuropathy [2]. Peripheral neuropathy is a 
deﬁning feature in some mitochondrial disorders such as 
SANDO (sensory ataxic neuropathy, dysarthria and 
minimum prevalence of peripheral neuropathy in patients with 
mitochondrial disorders, taking advantage of the large database 
built by the “Nation-wide Italian Collaborative Network of 
correlations are highlighted. 
2. Methods 
We reviewed the clinical data of all of the 1200 
histologically, biochemically and/or molecularly deﬁned 
patients present in our “Nation-wide Italian Collaborative 
Network of Mitochondrial Diseases” database (updated on 
December 31, 2014) and followed up by the involved centers, 
focusing on peripheral neuropathy as a clinical feature of a 
mitochondrial disorder. 
The database establishment (and its use for scientiﬁc 
purposes) was permitted by the local Ethical Committees of 
the single centers, which obtained written informed consent 
from all patients or their tutors, and has been performed in 
accordance with the ethical standards laid down in the 1964 
Declaration of Helsinki. This project has been supported by a 
Telethon grant (GUP09004). 
This is a retrospective study; all the involved centers have 
speciﬁc expertise in mitochondrial disorders. The clinical 
section of our web-based database includes “yes or no” 
dichotomic items agreed by all centers in a preliminary 
consensus phase. The consensus phase was speciﬁcally 
designed to include the clinical features known to be relevant in 
mitochondrial medicine [1]. The presence or absence of 
neuropathy, and its speciﬁc type (i.e., axonal versus 
demyelinating, motor versus sensory, polyneuropathy versus 
multiplex neuropathy – including mixed forms [2]) was 
requested to all centers for data elaboration. Clinical symptoms/ 
signs potentially suggestive of peripheral nerve dysfunction 
1. Introduction (i.e. numbness, paresthesia, hypotonia, weakness, muscle 
atrophy) have also been collected. Pure hereditary neuropathies 
(Charcot–Marie–Tooth disease – CMT) due to mutations in 
mitochondrial proteins, such as MFN2 and GDAP1 [3], have 
not been considered in this study, which addresses the classic 
OXPHOS disorders [4]. 
Results were expressed as means ± standard deviation. 
Comparisons of proportions have been performer by two-tailed 
Fischer’s exact test. A P value <0.05 was considered as 
signiﬁcant. Data analysis was carried out using MedCalc® 
Version 7.3.0.1. 
3. Results 
The clinical picture was fully available for 1156 patients 
(mean age at onset 24.3 ± 20.1 years; age at last evaluation 
39.8 ± 22.3 years; females 52.7%; childhood onset [before age 
ophthalmoplegia), NARP (neuropathy, ataxia and retinitis 16 years] 43.1%). Peripheral neuropathy was part of the clinical 
pigmentosa), or MNGIE (mitochondrial neuro-gastro-intestinal picture in 143/1156 patients (12.4%), being the tenth most 
encephalomyopathy) [3], and occasionally is the prevalent frequent clinical manifestation (Table 1). In 33 patients, 
disease manifestation [4,5]. However, the exact prevalence of neuropathy was present at the onset of the disease. 
peripheral neuropathy in mitochondrial disorders is still             In order to understand if the presence (or absence) of 
unknown [6].                                                                                       peripheral neuropathy was linked to speciﬁc molecular or 
The aim of this retrospective study is to evaluate the        clinical features, the patients of the Registry were divided in 
two groups, with and without neuropathy. Age at onset, age at 
last evaluation and gender ratio did not signiﬁcantly differ 
between the two groups. 
Mitochondrial Diseases”. Speciﬁc genotype–phenotype From a genotype-based point of view (Table 2), the mtDNA 
mutations associated with Leber hereditary optic neuropathy 
(LHON) had the lowest frequency in the group with neuropathy. 
The same was also observed in those patients harboring single 
mtDNA deletions (p < 0.000003). In contrast, mutations in the 
nuclear genes POLG, SURF1 and TYMP were those most 
consistently associated with peripheral neuropathy (Table 2). 
Table 1 
Clinical features at the last evaluation in mitochondrial patients. The table 
shows the 15 most common features, present in at least 100 cases. Migraine, 
cardiomyopathy,     retinopathy,     respiratory     impairment,     gastrointestinal 
dysmotility, cataract, stroke-like episodes, myoclonus, tremor, parkinsonism, 
dystonia, dyskinesias, psychiatric involvement, vomiting, hypothyroidism, 
anemia were rarer (2–8%). 
Patients % 
(n = 1156) 
Ptosis/ophthalmoparesis 
Muscle weakness 
Hearing loss 
Exercise intolerance 
Optic neuropathy 
Muscle wasting 
Cerebellar ataxia 
Cognitive involvement 
Hypotonia 
Neuropathy 
Swallowing impairment 
Epileptic seizures 
Muscle pain 
Pyramidal involvement 
Diabetes 
617 53.4 
446 38.6 
279 24.1 
239 20.7 
214 18.5 
212 18.3 
186 16.1 
180 15.6 
179 15.5 
143 12.4 
137 11.9 
131 11.3 
124 10.7 
112                                             9.7 
102                                             8.8 
From a phenotype-based point of view (Table 3), patients 
with neuropathy had an increased prevalence of ataxia, hearing 
loss, muscle weakness and muscle wasting. There was neither 
association with other neuromuscular symptoms, such as 
exercise intolerance and muscle pain, nor with other 
multisystem features, in particular diabetes. 
In those patients for whom muscle biopsy was available, 
ragged red ﬁbers were equally frequent in the group with (67/ 
96, 69.8%) or without (423/618, 68.4%) peripheral neuropathy. 
The same was observed for cytochrome c oxidase (COX)-
negative ﬁbers (81/96 [84.4%] and 470/618 [76.1%] 
respectively). Finally, considering the patients for whom plasma 
lactate levels were available, this biomarker was increased in 
58/98 (59.2%) patients with and in 322/632 (50.9%) patients 
without neuropathy, again a non-signiﬁcant difference. 
Among our patients with neuropathy, the “pure” forms were 
rare. Speciﬁcally, 55 patients had a pure axonal neuropathy, 18 
pure demyelinating, whereas 70 had a mixed/undeﬁned pattern. 
Furthermore, 14 patients had a motor neuropathy, 26 a sensitive 
form, whereas the remaining patients had a mixed/undeﬁned 
pattern. Finally, 94 patients have been deﬁned as having 
a length-dependent polyneuropathy, three as a multiplex 
neuropathy, and the remaining 46 as a different/undeﬁned 
pattern. Only 15 patients suffered of neuropathic pain. 
The relative rarity of the pure forms precluded a strict 
genotype–phenotype analysis, but some indications (shown in 
Table 4) were noted; among the POLG-mutated patients, 9 had 
a pure axonal – sensory or sensory-motor – neuropathy and 
only one a pure demyelinating sensory neuropathy; the 
prevalence of neuropathic pain seemed more frequent in POLG 
patients than in mitochondrial patients with neuropathy due to 
different genetic causes (see Table 5). 
Genotype-based approach. The patients have been divided in two groups, with 
and without neuropathy. Genotypes with less than ten patients have not been 
considered and are not shown. Signiﬁcance levels after Bonferroni’s correction 
0.0042. Signiﬁcant differences are represented in bold. LHON, Leber 
hereditary optic neuropathy. n.s., not signiﬁcant difference. 
Neuropathy: Neuropathy: P 
No (n = 1013) Yes (n = 143) 
mtDNA single deletion 
mtDNA A3243G mutation 
mtDNA A8344G mutation 
mtDNA T8993G (or C) mutation 
mtDNA LHON mutations 
Other mtDNA mutations 
OPA1 mutations 
POLG mutations 
Twinkle mutations 
SURF1 mutations 
PDHA1 mutations 
TP mutations 
218 (21.5%) 
90 (8.9%) 
30 (3.0%) 
12 (1.2%) 
103 (10.2%) 
53 (5.2%) 
72 (7.1%) 
26 (2.6%) 
22 (2.2%) 
10 (1.0%) 
11 (1.1%) 
2 (0.2%) 
9 (6.3%) 
12 (8.4%) 
5 (3.5%) 
6 (4.2%) 
1 (0.7%) 
7 (4.8%) 
5 (3.5%) 
19 (13.3%) 
6 (4.2%) 
10 (7.0%) 
1 (0.7%) 
9 (6.3%) 
0.000003 
n.s. 
n.s. 
0.017 
0.00002 
n.s. 
n.s. 
<0.000001 
n.s. 
0.00004 
n.s. 
<0.000001 
Table 3 
Phenotype-based approach. The patients have been divided in two groups, with 
and without neuropathy. Genotypes with less than ten patients have not been 
considered and are not shown. Signiﬁcance levels after Bonferroni’s correction 
0.0036. Signiﬁcant differences are represented in bold. LHON, Leber 
hereditary optic neuropathy. n.s., not signiﬁcant difference. 
Neuropathy: 
No (n = 1013) 
Neuropathy: 
Yes (n = 143) 
P 
Ptosis/ophthalmoparesis 
Muscle weakness 
Hearing loss 
Exercise intolerance 
Optic neuropathy 
Muscle wasting 
Ataxia 
Cognitive involvement 
Hypotonia 
Swallowing impairment 
Epileptic seizures 
536 (52.9%) 
362 (35.7%) 
220 (21.7%) 
203 (20.0%) 
195 (19.2%) 
169 (16.7%) 
131 (12.9%) 
148 (14.6%) 
152 (15.0%) 
119 (11.7%) 
110 (10.9%) 
81 (56.6%) 
84 (58.7%) 
59 (41.3%) 
36 (25.2%) 
19 (13.3%) 
43 (30.1%) 
55 (38.5%) 
32 (22.4%) 
27 (18.8%) 
18 (12.6%) 
21 (14.7%) 
n.s. 
<0.0001 
<0.0001 
n.s 
n.s 
0.0003 
<0.000001 
0.0045 
n.s. 
n.s. 
n.s. 
Muscle pain 
Pyramidal involvement 
Diabetes 
104 (10.3%) 
100 (9.9%) 
85 (8.3%) 
20 (14.0%) n.s. 
12 (8.4%) n.s. 
17 (11.9%) n.s. 
Table 2 Table 4 
Tentative phenotype-genotype correlations in mitochondrial neuropathy. 
POLG-associated neuropathy 
Prevalence 19/45 (42.2%), in ﬁve cases from the onset 
High prevalence of neuropathic pain (>1/3 – see Table 5) 
9 pure axonal, 1 pure demyelinating, 9 had mixed/undeﬁned pattern 
1 pure motor, 6 pure sensitive, 12 mixed/undeﬁned pattern 
11 length-dependent polyneuropathy, 1 multiplex neuropathy, 7 
different/undeﬁned pattern 
(axonal/mixed mainly sensory polyneuropathy) 
TP (TYMP)-associated neuropathy 
Prevalence 9/11 (81.8%), in no case from the onset 
Neuropathic pain is absent 
2 pure axonal, 5 pure demyelinating, 2 had a mixed pattern 
1 pure motor, 8 mixed sensori-motor pattern 
8 length-dependent polyneuropathy, 1 different/undeﬁned pattern 
(demyelinating sensory-motor polyneuropathy) 
SURF1-associated neuropathy 
Prevalence 10/20 (50.0%), in no case from the onset 
3 pure demyelinating, 7 had a mixed/undeﬁned pattern 
1 pure motor, 9 mixed sensori-motor/undeﬁned pattern 
6 length-dependent polyneuropathy, 4 different/undeﬁned pattern 
(demyelinating/mixed sensory-motor polyneuropathy) 
m.8993T > G or T > C mutation-associated neuropathy 
Prevalence 6/18 (33.3%), in one case from the onset 
5 pure axonal, 1 mixed/undeﬁned 
3 pure sensory, 3 mixed/undeﬁned 
5 length-dependent polyneuropathy, 1 different/undeﬁned pattern 
(axonal, mainly sensory polyneuropathy) 
Table 5 
Neuropathic pain and POLG-associated neuropathy. P = 0.000806 (Fisher’s 
exact test). 
POLG Other 
mutations etiologies 
Neuropathic pain: yes                    7                                  8                              15 
Neuropathic pain: no                   12                              116                            128 
19 124 
4. Discussion 
Despite the great progress in our genetic and clinical 
understanding of mitochondrial disorders, the prevalence of 
peripheral neuropathy is still unknown. Most of the published 
studies have examined single cases or families, or have been 
conducted by recruiting a limited number of patients [7]. Girlanda 
et al. analyzed 27 patients with unselected mitochondrial disease, 
and observed axonal neuropathy in six cases (18%) [8]. Mancuso 
et al. [9] showed electrophysiologically that peripheral neuropathy 
was present in about 35% of unselected mitochondrial patients, 
even if the peripheral nerve involvement was frequently 
subclinical. In the present study, taking advantage of a very large 
unselected cohort of mitochondrial disorders patients, including 
LHON and oligosymptomatic forms, we found a lower prevalence 
of peripheral neuropathy (12,4%), which could represent the 
minimum prevalence of peripheral neuropathy in mitochondrial 
disorders (13.5% [142/1052] if we exclude the patients with 
LHON). 
This preliminary survey presents the typical limitations of 
all retrospective studies, and may underestimate the real 
prevalence of neuropathy in patients with mitochondrial 
disorders. However, all the involved centers have strong 
expertise in clinical and electrophysiological assessment of 
neuromuscular disorders, which should minimize false negative 
or positive cases. Previous surveys [7–9], speciﬁcally designed 
for assessing the involvement of peripheral nervous system, 
also included patients with subclinical neuropathy, a criterion 
which can partially account for the discrepancy with the data 
presented here. 
Recently, Horga et al. [10] reported that peripheral 
neuropathy might suggest a nuclear gene defect in patients with 
mitochondrial progressive external ophthalmoplegia (PEO). In 
this study, 67% of PEO patients had a single mitochondrial 
DNA deletion, whereas 10% had a point mutation of mtDNA 
and 22% had mutations in either POLG, C10orf2, RRM2B, or 
had multiple mtDNA deletions in muscle without an identiﬁed 
nuclear gene defect. The prevalence of peripheral neuropathy 
was signiﬁcantly lower in patients with single, sporadic 
mitochondrial DNA deletion (2%) as compared to those with a 
mtDNA point mutation or with a nuclear DNA defect (44% and 
52%, respectively; P < 0.001) [10]. Therefore, our results 
conﬁrm the suggestion by Horga et al., that in PEO patients 
peripheral neuropathy is rarely found in association with single 
mtDNA deletions, whereas it is highly predictive of an 
underlying nuclear DNA defect [10,11]. Indeed, our data extend 
this concept to the entire population of mitochondrial 
patients, in addition to those with PEO; furthermore, we 
show that a “mitochondrial neuropathies” are predominantly 
associated with a few speciﬁc nuclear genes associated: 
POLG, TYMP and SURF1. This observation may facilitate the 
development of diagnostic algorithms suggesting nuclear gene 
testing in patients with mitochondrial disease and peripheral 
neuropathy, for a more rapid diagnosis, which can be achieved 
without performing a muscle biopsy. 
Furthermore, peripheral neuropathy with anesthesia leading 
to corneal scarring and acral mutilations is one of the major 
clinical features of Navajo neurohepatopathy, an autosomal 
recessive hepato-cerebral mtDNA depletion syndrome caused 
by a mutation in the MPV17 gene [12]. 
In our cohort, the subjects with neuropathy had an increased 
prevalence of ataxia, hearing loss, muscle weakness and muscle 
wasting. Therefore, neuropathy can cause and/or exacerbate 
neuromuscular symptoms that have a strong impact on the 
quality of life of these patients. 
Some phenotype–genotype correlations were highlighted in 
our study. In particular, POLG mutations can cause a potentially 
painful, axonal/mixed, mainly sensory polyneuropathy; 
TYMP mutations can lead to a demyelinating sensory-motor 
polyneuropathy (usually in the context of the MNGIE 
syndrome); SURF1 mutations lead to a Leigh (or Leigh-like) 
phenotype frequently associated with a demyelinating/mixed 
sensory-motor polyneuropathy. 
In our cohort, the only mtDNA mutation potentially 
associated with neuropathy is the m.8993T > G (or T > C) 
change, which can lead to an axonal, mainly sensory 
polyneuropathy. 
In conclusion, peripheral neuropathy is one of ten most 
common features of mitochondrial disease that potentially have 
a strong impact on the quality of life of these patients. Some 
genotype–phenotype correlations were highlighted, and the 
presence or absence of peripheral neuropathy, as well as its 
speciﬁc form and the association with neuropathic pain 
(indicative of a POLG-associated disease) can guide the 
molecular analysis. 
Prospective studies on clinical features in mitochondrial 
disorders are strongly needed; however, large multicenter 
retrospective studies help to characterize the clinical picture 
and natural history of rare diseases such as mitochondrial 
disease, and represent the basis for planning more rigorous 
longitudinal studies. 
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